If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Drug Combination Might Offer Hope for Patients Deadly Brain Tumors DURHAM, N.C. -- October 19, 2007 -- Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor's blood supply. According to a new study by researchers at Duke's Preston Robert Tisch Brain Tumor Center, a combination of bevacizumab -- commonly known as Avastin -- and a standard chemotherapy agent may increase the amount of time GBM patients can survive without tumor growth, and may significantly increase their overall survival. "For this study, we looked at patients whose tumors had returned after initial treatment, and we found that this drug combination could significantly improve outcomes for these people, who are typically given about three to six months to live," said James J. Vredenburgh, MD, a neuro-oncologist at Duke and lead investigator on the study. "These results represent tremendous hope for these patients and their families." The researchers published their findings in the October 20, 2007 issue of the Journal of Clinical Oncology and an editorial accompanied the publication. The study was funded by the National Institutes of Health, the Preston Robert Tisch Brain Tumor Research Fund and the Bryan Cless Research Fund. In this pilot study, researchers administered a combination of bevacizumab and irinotecan, a standard chemotherapeutic agent, to 35 patients whose GBMs had returned. Each patient had already been treated with a standard therapy regimen, possibly including surgery, radiation and chemotherapy. Almost half saw no tumor progression after six months, and almost 80% were still alive six months after diagnosis. Patients with recurrent GBM who are treated with standard therapies, such as chemotherapy alone, have tumor progression at six months in about 75% of cases and fewer than 50% are alive after six months. "Historically, when GBM recurred, there had typically been very little else we could do," said Vredenburgh. "We had one patient on this trial who had been already been told to get his affairs in order; he started the trial and over a year later he's still here, so this is very promising." Bevacizumab has been heralded as a success in treating several types of cancer, including colorectal and lung cancers. It is one member of a class of drugs called anti-angiogenics, which work by stunting the otherwise rapid growth of blood vessels that feed a tumor's growth and spread. "We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently or they work together, with the bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy," Vredenburgh said. "Further studies will tease out the exact mechanism of the therapy's success and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM." About 8,000 to 10,000 new cases of GBM are diagnosed each year in the United States, and GBMs account for about half of all primary brain tumors, according to Accelerate Brain Cancer Cure, a not-for-profit organization dedicated to hastening the discovery of effective treatments for brain cancer. Less than 30% of patients diagnosed with primary GBMs are alive one year after diagnosis, and after 10 years, only 2.3% are still alive. Even when GBMs are effectively treated with surgery or medicines, they return in more than 90% of all cases. Other study authors include Annick Desjardins, James Herndon II, Jennifer Marcello, David Reardon, Jennifer Quinn, Jeremy Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Melissa Wagner, Leighann Bailey, Darell Bigner, Allan Friedman and Henry Friedman.
SOURCE: Duke University Medical Center
|
